What is fibromyalgia?
Fibromyalgia is a complex chronic condition characterized by widespread pain across both sides of the body, above and below the waist, and along the axial spine. Rather than damage in the muscles or joints, fibromyalgia is understood as a central sensitization syndrome (or nociplastic pain), where the central nervous system amplifies sensory input and pain processing.
Key clinical features include:
- Widespread pain: Deep aching, throbbing, or burning across multiple tender areas.
- Chronic fatigue: Profound, unshakeable physical and mental exhaustion.
- Sleep dysfunction: Waking up feeling unrefreshed, even after a full night in bed.
- Cognitive dysfunction ("fibro fog"): Difficulty concentrating, memory lapses, and mental slowing.
- Allodynia: Heightened sensitivity where gentle pressure or light touch causes significant pain.
The regulatory divide: Why the UK differs from the US
Patients researching fibromyalgia online frequently see American websites describing Lyrica (Pregabalin) as a standard first-line treatment. Understanding why the UK approach differs is critical:
| Country / Authority | Licensing Status | Regulatory Rationale |
|---|---|---|
| United States (FDA) | Approved (since 2007) | Approved based on 8- to 14-week clinical trials showing a statistically significant proportion of patients achieved a ≥30% reduction in pain scores. |
| United Kingdom & Europe (MHRA & EMA) | NOT Licensed | Regulators concluded that long-term efficacy had not been proven, the magnitude of pain relief was modest, and the high incidence of adverse effects (weight gain, dizziness, sedation, and dependence potential) resulted in an unfavourable risk-benefit balance. |
| NICE (England & Wales) | Advised Against (NG193, 2021) | Recommends that antiepileptic drugs should not be initiated for chronic primary pain, prioritizing non-drug interventions and specific antidepressants. |
What does clinical research show?
A comprehensive Cochrane systematic review examining over 3,000 patients across randomized placebo-controlled trials found:
- Approximately 30% to 40% of patients taking 300mg to 450mg daily experienced at least a 30% reduction in pain severity (compared to about 25% on placebo).
- Patients often reported small improvements in sleep quality and fatigue.
- However, between 15% and 25% of patients dropped out early due to intolerable adverse effects, most notably dizziness, drowsiness, substantial weight gain, and peripheral fluid retention (oedema).
NICE Guideline NG193: The current UK approach
In 2021, NICE published guideline NG193 (Chronic primary pain in over 16s), which transformed how the NHS approaches fibromyalgia:
- Do NOT start: Gabapentinoids (Pregabalin, gabapentin), opioids, non-steroidal anti-inflammatory drugs (NSAIDs), or paracetamol.
- Consider specific antidepressants: Amitriptyline, citalopram, duloxetine, fluoxetine, paroxetine, or sertraline may be considered for adults aged 18 and over after discussing benefits and risks.
- Non-pharmacological priority: Supervised exercise programmes, psychological therapies (Acceptance and Commitment Therapy [ACT] or CBT), and acupuncture.
Why do some UK specialists still prescribe it off-label?
Despite NICE guidance, some consultant rheumatologists and tertiary NHS pain management centres prescribe Pregabalin off-label for selected individuals. Under GMC guidance, off-label prescribing is permitted when:
- First-line recommended options (such as exercise, duloxetine, or amitriptyline) have been thoroughly trialled and failed or were not tolerated.
- Severe sleep disruption and neuropathic-like burning pain are dominant symptoms.
- The clinician and patient discuss the off-label nature of the prescription, side effect risks, and set clear review dates to assess whether continuing is justified.
Holistic and non-drug strategies that help
Clinical evidence strongly demonstrates that fibromyalgia responds best to active, non-drug interventions rather than polypharmacy:
- Graded exercise and hydrotherapy: Warm-water pool exercises and gentle daily walking reduce central nervous system hypersensitivity.
- Pacing techniques: Learning to break tasks into manageable blocks to prevent the "boom-and-bust" cycle of overactivity followed by days of bed rest.
- Pain psychology (ACT & CBT): Acceptance and Commitment Therapy helps patients build fulfilling daily routines alongside chronic pain without constant struggle.
- Sleep hygiene: Strict sleep routines and addressing co-occurring sleep apnoea or restless legs syndrome.